Rounded incidence values (%) of renal and nonrenal events

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

Randomized, double-blind, multicenter, controlled trial.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source:

Clinical Outcomes with Newer Antihyperglycemic Agents

Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.

1 Combined CRD and DSaRM Advisory Committee Meeting Trasylol (aprotinin) NDA Overview George Shashaty, M.D. Division of Medical Imaging and Hematology.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

CRDAC & DSaRM Advisory Meeting September 12, 2007 Aprotinin Observational Studies Advisory Committee Meeting - September 12, 2007 Rita Ouellet-Hellstrom,

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Clinical Outcomes with Newer Antihyperglycemic Agents

(p for noninferiority = 0.01)

Discontinuation of medication after nonfatal event: MI

Clinical Outcomes with Newer Antihyperglycemic Agents

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

LEADER trial: Primary Outcome

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Section 3: CKD, CVD and mortality

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Valsartan in Acute Myocardial Infarction Trial Investigators

TNT: Baseline and final LDL cholesterol levels

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

Relative risk of major events with atenolol vs placebo

The US Renal Data System “Pie Chart of Death”

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Diabetes Journal Club March 17, 2011

Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials Sanjay Rajagopalan Journal of Indian College.

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

ONTARGET Non-inferiority Comparison

Cystatin C levels and risk of death from all causes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

The ONgoing Telmisartan Alone and in

Baseline Characteristics of the Study Participants

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Characteristics of the Patients - Part I

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cardiovascular risk in chronic kidney disease

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

End Points: ONTARGET vs. HOPE *

FIELD: Primary outcome

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

Outcomes Group Number of events Total person-years aIRR (95%CI)

Presentation transcript:

Rounded incidence values (%) of renal and nonrenal events Control Aminocaproic acid Tranexamic acid Aprotinin p Renal dialysis 1 5 <0.001 Renal dysfunction 2 3 Composite renal outcome 4 8 Death 0.004 Composite outcome 19 20 21 29 CV event 16 17 22 MI 13 12 <0.005 CHF 6 9 Stroke 0.08 Encephalopathy Composite renal outcome=renal dysfunction or renal failure requiring dialysis Composite outcome event=death, renal event, cardiovascular event, or cerebrovascular event Mangano DT et al. N Engl J Med 2006; 354:353-365.